Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,171 recruiting studies in this area right now.
By phase
- Not applicable9,517
- Phase 24,403
- Phase 12,662
- Phase 1/Phase 21,653
- Phase 31,392
- Phase 2/Phase 3284
- Phase 4260
Top conditions
- Breast Cancer1,197
- Prostate Cancer645
- Cancer634
- Colorectal Cancer481
- Lung Cancer417
- Ovarian Cancer337
- Multiple Myeloma329
- Pancreatic Cancer290
- Gastric Cancer283
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma256
- Solid Tumor246
- Advanced Solid Tumor234
- Head and Neck Cancer225
- Cervical Cancer224
- Endometrial Cancer209
- Advanced Solid Tumors202
- Esophageal Cancer191
Leading sponsors
- M.D. Anderson Cancer Center453
- Fudan University302
- National Cancer Institute (NCI)292
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University273
- Mayo Clinic238
- City of Hope Medical Center142
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences141
- AstraZeneca133
- Second Affiliated Hospital, Zhejiang University, School of Medicine128
Where studies are running
- California1,410
- Texas635
- Arizona509
- Florida435
- Alabama427
- New York404
- Massachusetts340
- Maryland330
- New Jersey271
- Pennsylvania234
Recruiting studies20,171 total
- NCT07509151RecruitingPhase 3
Surovatamig after first treatment for CLL or SLL
This trial tests a new drug called surovatamig as a follow-up treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already completed their first round of therapy. The goal is to see if it helps keep the cancer from coming back.
La Jolla, CaliforniaAges 18–18 - NCT07514143Recruiting
Bladder Cancer Detection Study Using Urine Test
This study tests a new urine-based test called EpiCheck to help detect bladder cancer. You'll provide urine samples before or during a bladder procedure you're already scheduled to have, and researchers will see how well the test works.
San Diego, CaliforniaAges 22 years+ - NCT07510802RecruitingPhase 1/Phase 2
CAR-NK cells for advanced HER2+ or triple-negative breast cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Shenzhen, GuangdongAges 18–75 - NCT07510815RecruitingPhase 1/Phase 2
Immune cell therapy for advanced mesothelioma
This trial tests a new type of immune cell therapy made from donor cells that are trained to target two specific proteins found on mesothelioma tumors. The goal is to see if these cells can safely shrink tumors or slow the disease when given directly into the chest or belly area.
Shenzhen, GuangdongAges 18–75 - NCT07516093RecruitingPhase 3
Comparing two drugs for advanced CLL or SLL
This trial tests whether NX-5948 is more effective than pirtobrutinib for people with CLL or SLL whose disease has gotten worse after an earlier BTK inhibitor treatment. It aims to find a better option for those who have already tried one type of therapy.
Macon, GeorgiaAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07508761RecruitingPhase 1/Phase 2
IPG7236 with Toripalimab for advanced solid tumors
This trial tests a new combination of two medications (IPG7236 and Toripalimab) for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if the combination is safe and effective.
Shanghai, PuDongXinQuAges 18 years+ - NCT07510828RecruitingPhase 1/Phase 2
CAR-NK cells for advanced solid tumors
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07512583RecruitingPhase 1/Phase 2
TQB2930 injection for advanced solid tumors with HER2 expression
This study tests a new injection called TQB2930 designed to treat advanced solid cancers (cancers that have spread) that have HER2 protein on their surface. The goal is to see if this treatment can shrink these tumors and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT06759714Recruiting
Epigenetic markers in newly diagnosed breast cancer
This study looks at specific molecules in the body that can change how your genes work (epigenetic mediators) in women who have just been diagnosed with breast cancer. The goal is to understand these markers better, which could help improve treatment in the future.
CairoAges 18 years+ - NCT06760221Recruiting
Spotlight on bone cancer: SBRT plus surgery
This trial tests if giving a high dose of focused radiation (SBRT) before surgery can improve outcomes for people with aggressive soft tissue sarcoma in an arm or leg. You may be able to avoid chemotherapy and still have a good result.
Hangzhou, ZhejiangAges 18–80 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT04803994RecruitingPhase 3
Atezolizumab plus bevacizumab versus TACE for liver cancer
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
GrazAges 18 years+ - NCT06090266RecruitingPhase 1/Phase 2
Study of OR502 alone and with other cancer treatments
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Austin, TexasAges 18 years+ - NCT07508605RecruitingPhase 1/Phase 2
CD19/CD20 CAR/TRuC-T cells for lymphoma that returned or didn't respond
This trial tests a new type of immune cell therapy that targets two markers (CD19 and CD20) on your lymphoma cells. It is for people whose lymphoma came back or didn't respond to previous treatments, including CD19 CAR-T therapy.
Shenzhen, GuangdongAges 18–75 - NCT07509099RecruitingPhase 3
Combination treatment for advanced head and neck cancer
This study tests a combination of two medications—cetuximab (a targeted antibody) and either pembrolizumab or finotonlimab (immunotherapies)—along with chemotherapy, for advanced head and neck cancer that has spread or come back. The goal is to see if this combination helps shrink tumors and improve survival compared to standard treatment.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07509333Recruiting
Personalized treatment planning for older adults with lung cancer
This study helps doctors create a personalized treatment plan for older adults with lung cancer based on a comprehensive review of their health. It aims to choose the best treatment to improve quality of life and outcomes.
Chengdu, SichuanAges 60–90 - NCT07514897Recruiting
Urine test to detect bladder cancer using CREPT protein
This study tests whether a protein called CREPT found in urine can help doctors diagnose bladder cancer or monitor patients who already have it. Researchers will compare urine samples from people with bladder cancer, people with other bladder conditions, and healthy volunteers.
Beijing, Chaoyang DistrictAges 18–75 - NCT07510334RecruitingPhase 2
VSV Virus Plus Immunotherapy for Advanced Kidney Cancer
This trial tests a combination of a special virus (VSV-IFNβ-NIS) with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced clear cell kidney cancer that hasn't been treated yet. It aims to see if this approach helps shrink tumors or slow the disease.
Rochester, MinnesotaAges 18 years+ - NCT07513116Recruiting
Intermittent fasting for people at high risk of pancreatic cancer
This study tests whether following an intermittent fasting schedule (eating only during certain hours) can help people at high risk for pancreatic cancer. The trial uses an app to track eating patterns and fasting times, aiming to see if this approach may reduce cancer risk.
Houston, TexasAges 18 years+ - NCT07507773RecruitingPhase 2
Radiation before surgery for limb or trunk wall sarcoma
This trial tests a shorter course of radiation given before surgery for soft tissue sarcoma in the arms, legs, or trunk wall. It aims to see if this approach works well long-term and may help you keep your limb.
LilleAges 18 years+ - NCT07510321Recruiting
A study of FL-261 imaging for cancer diagnosis
This trial tests a new imaging agent called FL-261 to help doctors see and stage cancers more clearly. If you have a known or suspected cancer like lung, colon, or head and neck cancer, this study may improve how your cancer is evaluated.
Wuhan, HubeiAges 18 years+ - NCT07508982RecruitingPhase 1/Phase 2
Combination therapy for high-risk acute myeloid leukemia
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
Houston, TexasAges 18 years+ - NCT07510724Recruiting
Real-world study of Tislelizumab for lung cancer
This trial collects information on how well the immunotherapy drug Tislelizumab works for different types of lung cancer. It is meant for people whose doctor already decided to prescribe this drug as part of their care.
Sankt Pölten, Lower AustriaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,171 recruiting oncology studies from the U.S. registry right now, out of 30,126 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.